Monitoring the hemodynamic response of portal pressure (PP) to drug therapy accurately stratifies the risk of variceal rebleeding (VRB). We assessed whether guiding therapy with hepatic venous pressure gradient (HVPG) monitoring may improve survival by preventing VRB. Patients with cirrhosis with controlled variceal bleeding were randomized to an HVPG-guided therapy group (N 5 84) or to a control group (N 5 86). In both groups, HVPG and acute b-blocker response were evaluated at baseline and HVPG measurements were repeated at 2-4 weeks to determine chronic response. In the HVPG-guided group, acute responders were treated with nadolol and acute nonresponders with nadolol1nitrates. Chronic nonresponders received nadolol1prazosin and had a third HVPG study. Ligation sessions were repeated until response was achieved. The control group was treated with nadolol1nitrates1ligation. Between-group baseline characteristics were similar. During long-term follow-up (median of 24 months), mortality was lower in the HVPG-guided therapy group than in the control group (29% vs. 43%; hazard ratio [HR] 5 0.59; 95% confidence interval [CI] 5 0.35-0.99). Rebleeding occurred in 19% versus 31% of patients, respectively (HR 5 0.53; 95% CI 5 0.29-0.98), and further decompensation of cirrhosis occurred in 52% versus 72% (HR 5 0.68; 95% CI 5 0.46-0.99). The survival probability was higher with HVPG-guided therapy than in controls, both in acute (HR 5 0.59; 95% CI 5 0.32-1.08) and chronic nonresponders (HR 5 0.48; 95% CI 5 0.23-0.99). HVPG-guided patients had a greater reduction of HVPG and a lower final value than controls (P < 0.05). Conclusion: HVPG monitoring, by stratifying risk and targeting therapy, improves the survival achieved with currently recommended treatment to prevent VRB using b-blockers and ligation. HVPG-guided therapy achieved a greater reduction in PP, which may have contributed to reduce the risk of rebleeding and of further decompensation of cirrhosis, thus contributing to a better survival. (HEPATOLOGY 2017;65:1693-1707. D espite improvements in therapy, recurrent variceal bleeding (VB) remains a leading cause of death in cirrhosis.
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(1) The combination of endoscopic variceal ligation (EVL) and bblockers is currently the recommended first-line treatment to prevent rebleeding, (1, 2) given that it is more effective than either treatment alone. (3) However, the effect of this combined therapy on survival is unclear. (3, 4) Uncontrolled studies have shown that a decrease in portal pressure (PP), assessed by the hepatic venous pressure gradient (HVPG), to < 12 mm Hg or by >20% from baseline is associated with a lower risk to develop complications of portal hypertension (PHT), such as bleeding or ascites. Even more important, these studies suggest that such a decrease in HVPG may achieve a significant improvement on survival, an effect rarely observed in randomized, controlled trial (RCTs) of therapy to prevent variceal rebleeding (VRB). (4) (5) (6) (7) (8) Furthermore, uncontrolled studies suggest that guiding therapy according to hemodynamic response can improve the outcomes of treatment to prevent bleeding. (9) (10) (11) A recent RCT also suggests that HVPG monitoring is useful in this setting. (12) In this study, HVPG-guided therapy was used to rescue patients without previous hemodynamic response to b-blockers plus isosorbide-5-mononitrate (ISMN) shifting to EVL. Using this HVPG-guided therapy survival was similar to that observed in patients treated with covered small-diameter transjugular intrahepatic portosystemic shunt (TIPS). (12) TIPS effectively reduces PP below risk thresholds and is useful to prevent bleeding. However, it does not improve survival, possibly because of its deleterious effects on liver function attributed to its portosystemic derivative nature. (13) Drugs can also ameliorate PHT, but may induce detrimental effects in cirrhosis as well. (14) HVPG monitoring may be valuable to guide therapy by stratifying risk, thus restricting treatments with a worse safety profile to high-risk patients. (3, 4) The hemodynamic effect of nonselective b-blockers, which are the mainstay of long-term drug treatment for PHT, (15) can be improved with the addition of ISMN. (9) Nonresponders to this combination may respond to b-blockers plus prazosin, which can achieve a high rate of hemodynamic response, but raises concern because it can cause arterial hypotension. (16, 17) This study aimed to assess whether, in the prevention of VRB, a therapy addressed to decrease PHT and adapted according to HVPG monitoring (involving bblockers alone or combined with ISMN or prazosin, and also involving EVL) can improve the survival achieved with b-blockers6ISMN plus EVL as currently recommended in guidelines.
Patients and Methods
From June 2005 to November 2010, patients with cirrhosis and VB admitted to either of the two participating hospitals were consecutively enrolled. Data collection ended in February 2012. The study protocol, approved by the institutional ethics committees and by the Spanish Ministry of Health, fulfilled the guidelines of Good Clinical Practice in Clinical Trials. All the patients or their next of kin gave written informed consent to participate in the study. No commercial support was involved in the study. All the authors vouch for the integrity and accuracy of the analysis and its fidelity to the protocol.
SELECTION OF PATIENTS
Patients with cirrhosis admitted to either of the two participating hospitals with melena and/or hematemesis confirmed by medical staff underwent emergency endoscopy and those with hemorrhage from esophageal varices were eligible for the study. Cirrhosis was diagnosed by previous liver biopsy or by compatible clinical, biochemical, and ultrasonographic findings. VB was diagnosed by endoscopy according to consensus criteria.
Patients with any of the following criteria were excluded: failure of medical therapy to control acute bleeding; Child-Pugh score greater than 12; advanced hepatocellular carcinoma (HCC); treatment with endoscopic therapy or with nonselective b-blockers plus ISMN within the previous 3 months; previous portosystemic shunt; concomitant disease with reduced life expectancy; bleeding from isolated gastric or ectopic varices; complete portal vein thrombosis (PVT) or portal cavernoma, PHT without cirrhosis; previous inclusion in the study; contraindication to both bblockers and ISMN; age < 18 years; pregnancy; and refused consent.
RANDOMIZATION AND STUDY PROTOCOL
On day 5/6 of admission, all patients were randomly assigned to a control group or an HVPG-guided therapy group. Allocation was concealed using sealed opaque envelopes containing the treatment assigned as derived from computer-generated random numbers.
Randomization was stratified according to severity of liver failure (Child-Pugh class A or B vs. C). The control group was treated with combined drug and endoscopic therapy using nadolol and ISMN plus EVL. The HVPG-guided group received pharmacological therapy tailored according to HVPG monitoring and EVL until hemodynamic response was achieved.
In both groups, a hemodynamic study was performed before randomization and acute hemodynamic response to b-blockers was evaluated (repeating measurements 20 minutes after 0.15 mg/kg of intravenous propranolol). A second study was conducted 2-4 weeks later to assess chronic response. Hemodynamic studies were performed according to recommended standards (Supporting Appendix). (4) PP was estimated from the HVPG. Hemodynamic response, either acute or chronic, was defined as a decrease in HVPG below 12 mm Hg or > 20% from baseline.
In the HVPG-guided group, treatment was tailored according to HVPG monitoring (Fig. 1) . Patients with acute response to b-blockers were treated with nadolol, and nonresponders were treated with nadolol and FIG. 1. Study design. In the HVPG-guided group, patients with acute hemodynamic response to b-blockers in the baseline study were treated only with nadolol and nonresponders were treated with nadolol plus ISMN. In the second hemodynamic study performed to assess chronic response to nadolol6ISMN, responders continue with same drug therapy and nonresponders were treated with nadolol plus prazosin and had a third hemodynamic study to assess final response. Furthermore, EVL sessions were stopped once hemodynamic response was documented. Patients in the control group were treated with nadolol plus ISMN and EVL during the complete study, whatever the effect on PP, which in this group was measured for the prognostic information only.
ISMN. Nonresponders in the second hemodynamic study were treated with nadolol and prazosin and had a third hemodynamic study 1-2 months later to determine final response. In this group, EVL was performed until hemodynamic response was documented and was discontinued thereafter.
In the control group, all patients were treated with nadolol1ISMN plus EVL, regardless of hemodynamic studies, which were only informative in this group.
TREATMENT AND FOLLOW-UP
In both groups, nadolol was started after randomization at an initial dose of 80 mg once-daily that was adjusted over 5 days to the maximum tolerated dose, keeping heart rate >55 beats per minute, or up to 240 mg/day. Thereafter, ISMN was added and progressively increased from 20 mg once a day up to 40 mg twice-daily (BID) over the course of a week. In the HVPG-guided group, chronic nonresponders to nadolol6ISMN received prazosin (instead of ISMN). Prazosin was increased stepwise from 1 mg at bedtime to 4 mg BID. Neither ISMN nor prazosin were increased when side effects developed or when systolic blood pressure fell below 95 mm Hg. Drug dosage was adjusted in follow-up visits. At each visit, heart rate and blood pressure were measured every 5 minutes for 30 minutes, tolerance and signs of fluid retention were investigated, and adherence to the regimen was assessed through careful questioning of patients and relatives.
EVL was performed using the same procedure in both groups. EVL was performed using a commercial multibanding device. Each varix was ligated at least once. Up to 14 bands were placed in the first session and up to seven bands in the following sessions, within the lower esophagus. Sessions were conducted every 3-4 weeks until variceal eradication. Varices were considered eradicated when they had disappeared or could not be grasped by the ligator. Thereafter, endoscopies were performed at 3 and 6 months and every 12 months. Additional sessions of ligation were conducted if varices reappeared. All procedures were performed under sedation with propofol. Proton-pump inhibitors were administered until eradication of varices. In the HVPG-guided group, EVL was discontinued once hemodynamic response was documented.
The index hemorrhage and rebleeding episodes were treated with somatostatin (or terlipressine), emergency EVL, and prophylactic antibiotics. During the acute bleeding episode, b-blockers were withdrawn at admission in patients who were treated with these drugs and they were restarted once patients had been randomized, after at least 5 days from the control of bleeding. In both groups, patients were visited at months 1 and 3 and then every 4 months. Data collection continued in all cases until the last enrolled patient had completed 1 year of follow-up. Ultrasonography was performed every 4-6 months.
ENDPOINTS AND DEFINITIONS
The primary outcome measure was death from any cause during follow-up. Secondary outcomes included rebleeding from any source, VRB, development of further decompensation of cirrhosis, side effects, HVPG response, and survival according to HVPG response. Data were collected for each outcome during the entire follow-up period.
Rebleeding was defined as any episode of hematemesis and/or melena occurring during the follow-up period and was evaluated by endoscopy. Therapeutic failure was defined as a single rebleeding requiring transfusion where the use of TIPS was considered. Further decompensation of cirrhosis was defined when bleeding, ascites, jaundice, or encephalopathy occurred. Ascites was defined as de novo development of ascites or worsening of preexisting ascites (requiring a sustained increase in diuretic dose or large-volume paracentesis). In all cases, it was confirmed by ultrasound and/or paracentesis. Hepatic encephalopathy was diagnosed on a clinical basis.
SAMPLE SIZE AND STATISTICAL ANALYSIS
Sample size was calculated assuming a 37% mortality in controls at 24 months of follow-up based on previous trials with standard care (7) and estimating a reduction to 17%, which is observed in hemodynamic responders in secondary prophylaxis. (3, 5) Using a twotailed test with alpha and beta values of 0.05 and 0.2, respectively, 77 patients were required for each group. This was increased by 10% to account for loss to follow-up.
Statistical analysis was performed according to an intention-to-treat strategy. Categorical variables were compared using Fisher's exact test. Continuous variables, reported as mean 6 SD, were compared using the Student t test. Within each group, continuous variables were compared using the Student t test for paired data. The Wilcoxon rank-sum test was used for skewed or ordinal data. Actuarial probabilities were calculated using the Kaplan-Meier method, and event rates of endpoints were compared using the log-rank test for the time to the first event after randomization. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were estimated using the Cox proportional-hazard model. The Cox regression model was also used to compare the two groups with respect to primary and secondary endpoints, adjusting for baseline risk factors (Child-Pugh, alcoholic cirrhosis, baseline HVPG, and age). Data were censored on the date of endpoint, at the time of liver transplantation (LT), at the time of the last documented visit, or at the end of the complete follow-up period, whichever occurred earliest. Patients who received an LT were censured as alive, and patients lost to follow-up were censored as if they had not developed any outcome after the last visit documented. Prespecified subgroup analyses were planned to assess the efficacy of the therapeutic strategy according to liver function and etiology of cirrhosis. P values were not adjusted for multiple comparisons. All P values were two-tailed, and values 0.05 were considered to indicate statistical significance. Calculations were performed with the SPSS statistical package (SPSS Inc., Chicago, IL, USA).
Results
During the study period, 1,049 patients were admitted for gastrointestinal bleeding (GIB) and 279 were screened, of whom 84 patients were randomized to the HVPG-guided therapy group and 86 to the control group (Fig. 2) . Both groups had similar baseline characteristics (Table 1 ). In the HVPG-guided group, 14 patients (18%) who had acute and chronic hemodynamic response to b-blockers were treated only with nadolol and 37 (44%) without chronic response to nadolol6ISMN were treated with nadolol plus prazosin. There were other procedural differences between the two groups: Patients in the HVPG-guided group had higher doses of nadolol, less use of ISMN, fewer EVL sessions performed, and fewer bands placed (Table 2) . Median length of follow-up was 24 months (interquartile range [IQR], 13 to 45), with no significant between-group difference ( Table 2) .
HEMODYNAMIC MEASUREMENTS
A baseline hemodynamic study was performed in 83 patients from each group. Baseline hemodynamic parameters were similar in both groups (Table 3) . A second hemodynamic study to investigate chronic response to nadolol6ISMN was performed in 78 patients in the HVPG-guided group and in 62 in the control group, after a mean time of 20 days (IQR, 13-30) versus 20 days (IQR, 15-30), respectively (P 5 0.54). The second hemodynamic study was not performed in 30 patients (24 controls): because of no previous baseline study in 4 cases (3 controls); baseline HVPG < 12 mm Hg in 4 (2 in each group); previous rebleeding in 6 (5 controls); no consent in 6 (4 controls); and decision of the attending physician in the remaining 10 (all controls). In the HVPG-guided therapy group, 37 of the 43 patients without chronic response to nadolol6ISMN received nadolol plus prazosin and underwent a third hemodynamic study to assess the final response. The third study was not performed in 6 nonresponders to nadolol6ISMN who did not receive prazosin because of difficult-to-control ascites.
Degree of b-blockade was similar in the two groups, as shown by decreases in heart rate and cardiac output
FIG. 2.
Patients assessed and enrolled in the trial. During the study period, 1,263 patients with GIB were screened and 977 not meeting the inclusion criteria were excluded. Of the 286 patients with esophageal VB screened for inclusion, 105 were excluded because of the following reasons: failure to control index bleeding (n 5 24); previous EVL (n 5 11) or TIPS (n 5 3) or treatment with b-blockers1ISMN (n 5 13); Child-Pugh score-> 12 points (n 5 15); advanced HCC (n 5 12); comorbidity with life expectancy <6 months (n 5 6); bleeding from gastric varices (n 5 10) or from ectopic varices (n 5 2); complete PVT (n 5 8); and age < 18 years (n 5 1). Finally, 174 patients were randomized and 4 of these (3 from the HVPG-guided therapy group) were withdrawn because they were found to be ineligible. (Table 3 ). Mean arterial pressure (MAP) decreased slightly and similarly in both groups, and cardiopulmonary pressures and systemic vascular resistance increased similarly in the two groups. These parameters did not change further in the HVPG-guided patients who received nadolol plus prazosin (Supporting Appendix).
HVPG decreased significantly in both groups (Table  3) . However, mean reduction was greater in the HVPGguided therapy group than in the control group (22 6 14% vs. 16 6 13%; P 5 0.02), and the final value of HVPG was lower. Rates of acute hemodynamic response to b-blockers and chronic response to nadolol6 ISMN were similar in both groups (Table 3) . However, the rate of final hemodynamic response was greater in the HVPG-guided therapy group. The final HVPG was <12 mm Hg in 9 of 78 (11%) patients in the HVPGguided group and in 4 of 62 (6%) controls (P 5 0.07).
MORTALITY
During the long-term follow-up, risk of mortality was lower in the HVPG-guided therapy group than in the control group: Death occurred in 24 patients (29%) in the HVPG-guided arm and in 37 (43%) controls (P 5 0.04; Fig. 3 ). Risk of mortality was unchanged after adjusting for baseline risk factors (HR 5 0.58; 95% CI 5 0.34-0.99). Early mortality, within the first 6 weeks, was not significantly different between the two groups: It occurred in 3 patients (4%) in the HVPG group and in 6 (7%) in the control group (HR 5 0.50; 95% CI 5 0.13-1.99). When patients with early death were excluded from the analysis, there was also a clear trend toward a reduced risk of overall mortality during the long-term follow-up, favoring the HVPG-guided therapy group (HR 5 0.58; 95% CI 5 0.34-1.01; P 5 0.058). The probability of transplant-free survival was better in the HVPG-guided therapy group than in controls (HR 5 0.62; 95% CI 5 0.39-1.00; P 5 0.05).
The benefit of HVPG-guided therapy was consistent across prespecified subgroups and appeared to be particularly pronounced in patients with advanced liver dysfunction (Child-Pugh score, 8) and in those with nonalcoholic cirrhosis (NAC; Fig. 3) .
Death attributed to liver failure occurred in 14 patients (17%) in the HVPG-guided group and in 23 (27%) controls (P 5 0.09). An exploratory post-hoc analysis, classifying deaths as related or nonrelated to cirrhosis, showed that the improvement in mortality was mainly related to a decrease in liver-related deaths (19% in the HVPG-guided group vs. 37% in the control group, HR 5 0.44; 95% CI, 0.24-0.81). Death was not related to cirrhosis in 8 patients (9%) in the HVPG-guided group and in 4 (5%) in the control group (P 5 0.27). A breakdown of cause of death is provided in the Supporting Appendix. Figure 4 shows the long-term mortality according to the treatment finally received within the HVPG-guided group. Overall, survival probability was higher in acute hemodynamic responders to b-blockers (in the baseline study) than in nonresponders (P 5 0.001; Supporting Appendix) and also in chronic responders to bblockers6ISMN (in the second study) than in nonresponders (P 5 0.05; Fig. 4) . In acute nonresponders to b-blockers, survival probability was slightly higher in the HVPG-guided group than in controls (HR 5 0.59; 95% CI 5 0.32-1.08; Supporting Appendix). In chronic nonresponders to b-blockers6ISMN, the survival probability was significantly higher in the HVPG-guided group than in controls (HR 5 0.48; 95% CI 5 0.23-0.99; Fig. 4 ).
RECURRENT BLEEDING
Risk of rebleeding during follow-up was lower in the HVPG-guided group than in controls: Rebleeding *Plus-minus values are means 6 SD. † Eleven patients (9 of the control group) had a follow-up of only 1 month or less: 9 of them died and 2 were lost to follow-up after discharge. ‡ Seven patients of the guided-therapy group and 6 controls were lost to follow-up. Among patients lost to follow-up, mean follow-up time in the HVPG-guided group was 14 months (IQR, 12-36) and in controls was 13 months (IQR, 2-26). § Three patients (1 of the HVPG-guided group) did not received nadolol because of contraindications. ¶ Withdrawal of nadolol occurred in 10 patients of the HVPG-guided group and in 14 controls. Withdrawal was attributed to side effects in 8 cases (4 controls), noncompliance in 5 (3 controls), or therapeutic failure in 11 (7 controls). k ISMN was not administered in 18 patients of the HVPG-guided group because of acute hemodynamic response to b-blockers and in 1 control because of contraindication. **Withdrawal of ISMN occurred in 45 patients of the HVPG-guided group and in 16 controls, because of absence of hemodynamic response to nadolol6ISMN in 37 patients of the HVPG-guided group, because of side effects in 3 cases (2 controls), noncompliance in 4 (3 controls), or therapeutic failure in 17 (11 controls). † † In the HVPG-guided therapy group, nadolol plus prazosin was administered to 37 patients among the 43 without chronic response to nadolol6ISMN, whereas 6 nonresponders to nadolol6ISMN did not receive prazosin because of difficulty to control ascites. ‡ ‡ Withdrawal of prazosin occurred in 9 patients because of side effects (2 cases), noncompliance (2 cases), or therapeutic failure (5 cases). § § Total number of sessions of EVL performed during the follow-up and total number of bands placed. ¶ ¶ Failure to eradicate varices occurred in 25 patients in the HVPG-guided group versus 31 controls and was attributed to previous therapeutic failure in 3 of 25 (12%) versus 18 of 31 (58%) of cases (P 5 0.02), previous hemodynamic response in 22 of 25 (88%) versus 0 cases (P < 0.001), and no consent or not clarified reasons in the remaining 13 controls.
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from any cause occurred in 16 patients (19%) in the HVPG-guided arm and in 27 (31%) controls (P 5 0.04; Table 4 ). Risk of rebleeding was also lower in the HVPG-guided group after adjusting for baseline risk factors (HR 5 0.51; 95% CI 5 0.26-0.95). The effect was consistent across subgroups (Table 4) .
Risk of VRB and therapeutic failure were not significantly lower with HVPG-guided therapy (Table 4) . Therapeutic failure occurred in 13 patients (15%) in the HVPG-guided arm and in 22 (26%) controls (Table 4) . Among these failures, 10 HVPG-guided patients (12%) and 15 (17%) controls received rescue Results expressed as mean 6 SD. *In the HVPG-guided group, a second hemodynamic study was performed after 22 6 12 days from the baseline study to assess response to nadolol6ISMN. † In the HVPG-guided group, 37 patients were treated with nadolol plus prazosin because of previous non -response to nadolol6 ISMN and had a third hemodynamic study to assess final response (after 56 6 22 days from baseline). In the remaining 41 patients, the final hemodynamic assessment was that of the second study performed with nadolol6ISMN. ‡ In the control group, a second hemodynamic study was performed after 23 6 14 days from the baseline study to assess response to nadolol plus ISMN. § P < 0.01 for the comparison with the baseline value. ¶ P < 0.05 for the comparison with the baseline value. k P 0.05 for the comparison between values of both groups. **Hemodynamic response, either acute or chronic, was defined as a decrease in HVPG below 12 mm Hg or > 20% from baseline. † † In the HVPG-guided group, a baseline hemodynamic study was performed in 83 patients, intravenous propranolol was administered to 80 of them and hemodynamic response was observed in 18 (3 had a decrease in HVPG to <12 mm Hg). In the control group, a baseline study was performed in 83 patients, intravenous propranolol was administered to 73 of them and response was observed in 14 (P 5 0.69 vs. HVPG-guided group; 3 controls had a decrease in HVPG to <12 mm Hg). ‡ ‡ In the HVPG-guided group, a second study was performed in 78 patients and response was observed in 35 (6 had a decrease in HVPG to <12 mm Hg). In the control group, a second hemodynamic study was performed in 62 patients and hemodynamic response was observed in 30 (P 5 0.73 vs. the HVPG-guided group; 4 controls had a decrease in HVPG to <12 mm Hg). § § In the HVPG-guided therapy group, among the 43 cases without chronic response to nadolol6ISMN, nadolol plus prazosin was administered to 37 patients who had a third hemodynamic study and response was observed in 18 of them (49%). Accordingly, final hemodynamic response was observed in 53 patients (68%) of the HVPG-guided group versus 30 (48%) of the control group (P 5 0.02). 
FURTHER DECOMPENSATION OF CIRRHOSIS AND COMPLICATIONS
Risk of further decompensation of cirrhosis during follow-up was lower in the HVPG-guided group than in controls ( Table 4 ). The benefit of HVPG-guided therapy was consistent across prespecified subgroups and appeared to be particularly pronounced in advanced liver dysfunction and in NAC (Table 4) . There was a slightly lower risk of developing ascites with HVPG-guided therapy, although the difference was not significant. There was also a clear trend toward a lower risk of developing encephalopathy, favoring HVPG-guided therapy (Table 4) . Liver function, assessed by Child-Pugh score and Model for End- Flow of patients in the HVPG-guided group with numbers of patients receiving each planned therapy according to hemodynamic response and the long-term mortality in each of the resulting subgroups (according to the therapy finally received). Acute b-blocker test was not performed in 4 patients (1 had no baseline hemodynamic study, and in 3, intravenous propranolol was not administered). The second hemodynamic study was not performed in 6 patients of this group because of no previous baseline study (n 5 1), baseline HVPG < 12 mm Hg (n 5 2), previous rebleeding (n 5 1), or no consent (n 5 2; 1 of them died). Among the 43 cases without response to nadolol6ISMN in the second study, nadolol plus prazosin was administered to 37 patients whereas 6 nonresponders did not receive prazosin because of difficult to control ascites. (B) Kaplan-Meier estimates of survival according to chronic hemodynamic response to nadolol6ISMN. Probability was higher in chronic responders than in nonresponders (P 5 0.05 by log-rank test). (C) Kaplan-Meier estimates of survival in the subgroup of patients without chronic hemodynamic response to nadolol6ISMN, according to treatment group. Probability was higher in the HVPG-guided group than in the control group (P 5 0.03 by log-rank test).
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Stage Liver Disease (MELD) score, improved similarly in both groups (Table 2) . Overall, probability of further decompensation of cirrhosis was lower in acute (P 5 0.001) and in chronic (P 5 0.001) hemodynamic responders to b-blockers6 ISMN than in nonresponders (Supporting Appendix). The probability of further decompensation of cirrhosis was slightly lower in the HVPG-guided group than in controls among acute nonresponders to b-blockers (HR 5 0.69; 95% CI 5 0.44-1.08). In chronic nonresponders to b-blockers6ISMN, the probability of further decompensation was significantly lower in the HVPG-guided group than in controls (HR 5 0.52; 95% CI 5 0.31-0.89).
There were no significant between-group differences in the rates of overall adverse events or serious adverse events (Table 4) . A breakdown of adverse events is presented in the Supporting Appendix. No complication was fatal or attributed to hemodynamic measurements.
Discussion
The present study shows that HVPG-guided therapy, aiming to decrease PHT and stratify risk according to the effect on PP, significantly improves the survival achieved with current first-line treatment to prevent VRB in cirrhosis. This can be related to the greater improvement in PHT achieved with HVPG-guided therapy. As suggested by our results, such an improvement in PHT may be associated with a better control of factors contributing to death, such as rebleeding or further decompensation of cirrhosis. The mortality observed in our control group was higher than that reported previously. (3, 15, 18) The longer follow-up in Percentages are crude rates of events occurring at any time during the follow-up. Plus-minus values are means 6 SD. *Values indicate the HR of an outcome in the guided-therapy group as compared to the control group. † Rebleeding could not be related to PHT in 3 patients of the HVPG-guided group (1 patient bleed from peptic ulcer and endoscopy was not performed in 2 cases) and in 4 controls (2 patient bleed from peptic ulcer, 1 from angiomata and endoscopy was not performed in 1 case). ‡ Therapeutic failure occurred in 13 patients in the HVPG-guided group in a median time of 6 months (IQR, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] and in 22 in the control group in a median time of 3 months (IQR, 1-11). All VRB episodes were therapeutic failure. § When therapeutic failure occurred, TIPS was placed in 10 patients of the HVPG-guided group in a median time of 4 months (IQR, 2-9) and in 15 controls in a median time of 2 months (IQR, 1-4). ¶ Thirty-four patients in the HVPG-guided group and 35 in the control group had at least one adverse event during follow-up. k Adverse effects were considered severe if the health or safety of the patient was endangered.
this study compared to previous trials, the worse liver dysfunction, and the low rate of exclusions may have accounted for this, as suggested by the fact that mortality in the HVPG-guided group was also higher than in most previous trials. (3, 15, 18) Furthermore, the present survival estimates at 1 and 2 years of follow-up are comparable to those previously reported.
Previous RCT assessing therapy to prevent VRB have rarely observed a survival benefit in this high-risk setting, even when rebleeding was reduced. (15, 18) However, uncontrolled studies have shown that, in addition to reducing the risk of rebleeding, substantial reductions in PHT (i.e., HVPG decrease to <12 mm Hg or > 20% from baseline) can also decrease the risk of other complications related to PHT, (5) (6) (7) (8) and such reductions in HVPG are also associated with an improvement in survival. (5) (6) (7) (8) The results of these studies suggest that HVPG monitoring may successfully stratify risk and guide therapy. (9) (10) (11) Accordingly, in the experimental group, we used HVPG monitoring to guide therapy. Treatments with a poor safety profile were restricted to high-risk patients who did not have a previous hemodynamic response. Because responders to b-blockers show no further decrease in HVPG when vasodilators are added, (16) acute responders to bblockers received nadolol only. Acute nonresponders received nadolol plus ISMN. Chronic nonresponders to nadolol6ISMN were treated with b-blockers plus prazosin, which can achieve response in these cases. (16, 17) Furthermore, EVL sessions were only repeated until hemodynamic response was documented. Thus, in the HVPG-guided group, we restricted the use of drugs combinations with greater efficacy to decrease PHT, but with worse safety profile, to high-risk patients without previous response to safer therapies. Use of EVL, an endoscopic therapy with potential serious side effects, was also restricted in this group. On the other hand, all patients in the control group received nadolol, ISMN, and EVL whatever the effect on HVPG. Using this approach, we achieved a greater reduction of PHT in the HVPG-guided group than in controls, with a lower final HVPG value and a higher rate of final hemodynamic response. In keeping with previous uncontrolled studies, (10, 11) it is likely that the better control of PHT contributed to improving the outcomes with HVPG-guided therapy. The potential role of restricting harmful treatments is not supported by our results, because the incidence of complications related to therapy was similar in both groups. However, an undetected benefit cannot completely be ruled out. Whatever the case, this study clearly suggests that a therapy successfully addressed to ameliorate PHT and targeted according to risk stratified by HVPG monitoring can significantly improve survival.
The improvement in survival that we observed with HVPG-guided therapy probably goes beyond the effect on rebleeding. It can also be related to better prevention of other potential causes of decompensation of cirrhosis. We observed a trend toward a reduced risk of developing ascites with HVPG-guided therapy and an even stronger trend toward a reduced risk of encephalopathy, although the differences were not significant. The rates of these outcomes were within the highest range reported (7, 12, 19, 20) and can be attributed, as previously commented, to factors such as longer follow-up, worse liver dysfunction, and lower rate of exclusions in this study than in previous studies. (3, 15, 18) PHT is a major determinant in the transition of cirrhosis to decompensated stages with higher morbidity and mortality. (21) Decompensated cirrhosis attributed to VB constitutes a high-risk setting with greater mortality than while in the compensated stage. (3, 4) Mortality is even greater when, in addition to bleeding, patients develop further decompensation of cirrhosis. (21, 22) In keeping with previous uncontrolled studies, (10, 11) our results suggest that HVPG-guided therapy may improve risk of developing further decompensation, thus contributing to improve survival.
Our results are consistent with previous studies, suggesting that, to prevent VB, drug therapy (aimed to decrease PHT) can improve the long-term survival achieved with EVL, despite no significant effect on rebleeding. (11, 23, 24) However, conflicting results have been observed in trials using TIPS, a therapy that effectively reduces PHT. These studies have shown that although TIPS significantly decreased rebleeding as compared to endoscopic therapy or drugs, it also increased the incidence of encephalopathy and had no effect on survival. (13, 25, 26) These detrimental effects can be related to the portosystemic derivative nature of TIPS, which can be deleterious to liver function. In fact, in one study, pharmacological therapy achieved a more-pronounced improvement in liver function than TIPS. (25) Conversely, it has recently been shown that the use of early TIPS after an acute VB episode may achieve favorable results, even improving survival, when restricted only to high-risk patients. (20) This reinforces the value of risk stratification to adapt treatment, such as in the present study, in order to improve the prognosis of patients who have recovered from a variceal hemorrhage. (4, 22) The subgroup analysis of this study suggests that, in addition to HVPG-monitoring, severity of liver dysfunction may help to improve risk stratification. In previous studies, liver dysfunction has consistently shown a good prognostic value of bleeding and death. (3, 4, 22) In concordance with these studies, (20) our subgroup analysis suggests that invasive strategies (such as HVPG-guided therapy or early TIPS) may be particularly effective in patients with more-advanced liver disease, such as those with Child-Pugh score 8, with a higher risk of poor outcome. Several issues deserve comment regarding the guided therapy used in this study. Combined treatment with b-blockers and prazosin is highly demanding, requires close monitoring, and has a narrow safety profile in cirrhosis. (14) Other therapies may overcome these drawbacks. Use of early TIPS in selected highrisk patients, (20) and several drugs or drug combinations, such as carvedilol, b-blocker plus simvastatin, antifibrotics, antioxidants, antiangiogenics, or the selective hepatic delivery of vasodilators, are currently under investigation. (27, 28) Effective etiological treatments, such as direct-acting antiviral agents in HCV, in addition to stopping disease progression, may also achieve target reductions in PP, which should be considered. (29, 30) Use of HVPG monitoring also constitutes a drawback of the study. Although HVPG is currently the best surrogate marker of PHT, (31) it is invasive and not widely available. Noninvasive procedures to assess PHT, such as transient elastography and acoustic radiation force impulse, are also under investigation. (32, 33) Another issue to consider regarding HVPG monitoring is the time lapse up to remeasurement in a second hemodynamic study, in order to adapt therapy according to response. This constitutes a high-risk period, particularly in the setting of secondary prophylaxis, where the incidence of early rebleeding is high. (34) As shown in the current study, as well as in previous reports, (3, 5) the proportion of patients who bleed before the second hemodynamic evaluation is not negligible. To minimize this risk, we shortened, as compared with previous studies, (3, 5) the time interval between hemodynamic measurements up to a mean of only 20 days. This may have helped to improve outcomes with HVPG-guided therapy. Future studies should assess whether even shorter time intervals between measurements, or other factors, such as the potential role of acute hemodynamic response in a single study or the use of faster therapeutic alternatives (such as an early decision for TIPS), may improve the results achieved in the present study.
Whether or not combined therapy with EVL and b-blockers plus prazosin may be an adequate first-line treatment to prevent rebleeding cannot be inferred from our results. By using HVPG monitoring, we adapted therapy to risk. Thus, 19% of patients were treated only with b-blockers, prazosin was administered to less than half the patients, and EVL requirements were significantly reduced. This may have favored a better risk/benefit ratio than widespread use of b-blockers plus prazosin. Furthermore, carvedilol, a promising drug to treat PHT, shares similarities with the combination of nadolol and prazosin associating both a b-and a1-blocker effect. (35) However, with the combined therapy, both effects can be titrated separately, thereby allowing maximal b-blocker activity while minimizing a-blocker. This may result in better outcomes, because the efficacy of b-blockers improves with high doses, (3, 4) whereas minimizing a-blocker activity may reduce undesirable effects linked to vasodilatation in cirrhosis, such as hypotension, which may favor sodium and water retention. (14) This study has several potential limitations. Although the risk of bias was minimized through a robust primary outcome and allocation concealment, the study was not blinded and this may have introduced undetected bias. Furthermore, the results cannot be generalized to all patients treated to prevent VRB. Patients with advanced liver dysfunction were not included, among others. Nevertheless, this is a general issue in this setting because current exclusion criteria were commonly used in previous RCTs. (3, 15, 18) Our results cannot be generalized to primary prophylaxis or to patients with PHT without cirrhosis. These are settings with lower baseline risk of bleeding. (22, 31) Whether PP-guided therapy may be beneficial for these indications should be properly investigated. In addition, we observed differences with borderline P values and without correction for multiple testing, which should be interpreted with caution given that they may have occurred by chance. Therefore, additional studies will be valuable to confirm the benefit of HVPG-guided therapy.
In conclusion, this study shows that use of HVPG monitoring to stratify risk and guide therapy to ameliorate PHT (involving b-blockers alone or combined with isosorbide mononitrate or with prazosin, and also involving EVL) significantly improves the survival achieved with current first-line treatment to prevent VRB utilizing b-blockers and ligation. HVPG-guided therapy achieved a greater reduction of PHT, which may have contributed to better outcomes. Our results suggest a reduced risk of rebleeding and further decompensation of cirrhosis with HVPG-guided therapy, possibly contributing to the survival benefit.
